Friday, August 30, 2019

Live Webinar - Optimization of a Pharmaceutical Granulation Process using Quality by Design (QbD)

 Optimization of a Pharmaceutical Granulation Process using Quality by Design (QbD)
Date: September 27, 2019 
Time: 2:00 PM - 3:30 PM  
Cost: CAD$345.00+HST

Location: AAPS Training Center
200 Consumers Road, Suite 200 North York, Ontario M2J 4R4 Canada
Telephone: 416-502-2277  
Course overview

For many years pharmaceutical companies have placed considerable effort in developing robust manufacturing processes to assure the highest quality products, minimize defects, eliminate rejects and conform to all Regulatory requirements. These processes are developed by scientists using past knowledge and 1 variable-at-a-time experiments and then subjected to process validation. Unfortunately, more often than not, even validated processes fail.

At the core of this problem is the fact that full process knowledge has not been acquired and all critical factors have not been identified. This implies that the manufacturing process can drift into a region not fully explored and produce an output that falls outside acceptable limits.

In this webinar participants will learn about

  • Basic concepts of Quality by Design (QbD)
  • Advantages of QbD over traditional 1 variable-at-a-time experimentation
  • Statistical experimental design
  • Critical factors
  • Factor interactions
  • Design space
  • Interpretation of data derived from QbD
  • A real life example of QbD applied to a pharmaceutical granulation process to fully understand the critical factors and the optimal operating range within the design space for those factors


Who should attend

The webinar is suitable for those who are seeking to get a basic understanding of the concept of Quality by Design and its application to pharmaceutical processing including personnel in Production, Quality Assurance, Quality Control, Validation and Development.
what's happening on our social sites:
Copyright ® 2019 Academy of Applied Pharmaceutical Sciences (AAPS) Inc.

No comments:

Post a Comment